Hospital Miguel Servet -ko ikertzaileekin lankidetzan egindako argitalpenak (23)

2024

  1. Role of factor XIII in ischemic stroke: a key molecule promoting thrombus stabilization and resistance to lysis

    Journal of Thrombosis and Haemostasis, Vol. 22, Núm. 4, pp. 1080-1093

  2. Transcriptomic Analysis of Extracellular Vesicles in the Search for Novel Plasma and Thrombus Biomarkers of Ischemic Stroke Etiologies

    International journal of molecular sciences, Vol. 25, Núm. 8

2023

  1. Recommendations for the Clinical Approach to Immune Thrombocytopenia: Spanish ITP Working Group (GEPTI)

    Journal of Clinical Medicine, Vol. 12, Núm. 20

2022

  1. Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: A randomized, open-label study

    European Journal of Cancer, Vol. 174, pp. 243-250

  2. SEA 2022 Standards for Global Control of Cardiovascular Risk

    Clinica e Investigacion en Arteriosclerosis, Vol. 34, Núm. 3, pp. 130-179

2021

  1. Engraftment after autologous hematopoietic stem cell transplantation in patients mobilized with Plerixafor: A retrospective, multicenter study of a large series of patients

    Transfusion and Apheresis Science, Vol. 60, Núm. 3

  2. Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia

    Leukemia, Vol. 35, Núm. 8, pp. 2358-2370

  3. Treatment of steroid-refractory chronic graft-versus-host disease with imatinib: Real-life experience of the Spanish group of hematopoietic transplantation (GETH)

    Clinical Transplantation, Vol. 35, Núm. 5

2020

  1. Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project

    Haematologica, Vol. Online ahead of print

2019

  1. Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial

    Cancer Medicine, Vol. 8, Núm. 16, pp. 6955-6966

  2. Standards for global cardiovascular risk management arteriosclerosis

    Clinica e Investigacion en Arteriosclerosis, Vol. 31, pp. 1-43

2017

  1. ¿Es posible la regresión de la placa aterosclerótica?

    Clinica e Investigacion en Arteriosclerosis

2016

  1. Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under lendex: A longitudinal analysis

    Blood, Vol. 127, Núm. 9, pp. 1151-1162

  2. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial

    The Lancet Oncology, Vol. 17, Núm. 8, pp. 1127-1136

2015

  1. Foro de debate: Seguridad de las alternativas a la transfusión alogénica en el paciente quirúrgico y/o crítico

    Medicina Intensiva, Vol. 39, Núm. 9, pp. 552-562

2013

  1. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma

    New England Journal of Medicine, Vol. 369, Núm. 5, pp. 438-447

  2. MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström's macroglobulinemia

    Leukemia, Vol. 27, Núm. 8, pp. 1722-1728

2012

  1. Myelodysplasia-associated immunophenotypic alterations of bone marrow cells in myeloma: Are they present at diagnosis or are they induced by lenalidomide?

    Haematologica, Vol. 97, Núm. 10, pp. 1608-1611

  2. POEMS syndrome with severe neurological damage clinically recovered with lenalidomide

    Haematologica

2011

  1. Effect of phlebotomy on lipid metabolism in subjects with hereditary hemochromatosis

    Metabolism: Clinical and Experimental, Vol. 60, Núm. 6, pp. 830-834